The harsh portfolio!

As of today, I have shifted my 2% allocation from Lupin to Lincoln Pharma. There is a lot of near term uncertainty with Lupin (on sales and margin front), Lincoln on the other hand finished their capex and should commercialize their cephalosporin facility this quarter. This should trigger a 20-25% growth in FY23 (link to management interview). Previously, management has overguided and underdelivered which is clearly reflected in the kind of valuations they trade at. Cash remains at zero.

Core compounder (48%)

Companies Weightage
I T C Ltd. 8.00%
Housing Development Finance Corporation Ltd. 4.00%
NESCO Ltd. 4.00%
Eris Lifesciences Ltd. 4.00%
Ajanta Pharmaceuticals Ltd. 4.00%
HDFC Asset Management Company Ltd 4.00%
Aegis Logistics Ltd. 4.00%
Gufic Biosciences 4.00%
HDFC Bank Ltd. 2.00%
PI Industries Ltd. 2.00%
Control Print Limited 2.00%
Shri Jagdamba Poly 2.00%
ICICI Lombard General Insurance Company Ltd. 2.00%
LINCOLN PHARMACEUTICALS LTD. 2.00%

Cyclical (36%)

Companies Weightage
Kolte-Patil Developers Ltd. 4.00%
Sharda Cropchem Ltd. 4.00%
Avanti Feeds Ltd. 4.00%
Aditya Birla Sun Life AMC Ltd 4.00%
Manappuram Finance Ltd. 4.00%
Alembic Pharmaceuticals Ltd. 4.00%
Amara Raja Batteries Ltd. 4.00%
Ashiana Housing Ltd. 2.00%
Ashok Leyland Ltd. 2.00%
SWARAJ ENGINES LTD. 2.00%
Kaveri Seed Company Ltd. 2.00%

Slow grower (4%)

Companies Weightage
Cochin Shipyard Ltd. 4.00%

Turnaround (6%)

Companies Weightage
CARE Ratings Ltd. 4.00%
Punjab Chem. & Corp 2.00%

Deep value (6%)

Companies Weightage
ATUL AUTO LTD. 1.00%
Jagran Prakashan Ltd. 1.00%
D.B.Corp Ltd. 1.00%
Time Technoplast Ltd. 1.00%
RACL Geartech Ltd 1.00%
Shemaroo Entertainment Ltd. 1.00%
14 Likes